Post-Treatment Surveillance for CDKN2A Mutated Pancreatic Cancer

Surveillance Protocol After Pancreatic Cancer Treatment

CDKN2A mutation carriers who have been treated for pancreatic cancer require lifelong annual surveillance of the remnant pancreas due to their persistently elevated risk of developing new primary pancreatic cancers, with imaging intervals shortened to 3-6 months if concerning abnormalities develop 1, 2
Annual surveillance is mandatory for CDKN2A carriers post-treatment, alternating between MRI/MRCP and Endoscopic ultrasound (EUS) 3, 4
For concerning abnormalities that do not warrant immediate surgery, perform additional testing with EUS-FNA and repeat imaging within 3-6 months 1, 2, 3

Routine fasting blood glucose and/or HbA1c testing should be performed at each surveillance visit, and new-onset diabetes should trigger immediate investigation 5, 3
CA19-9 should be measured when worrisome features appear on imaging, but is not recommended for routine surveillance in asymptomatic patients 3, 4

Solid lesions ≥5 mm, cystic lesions with worrisome features, and asymptomatic main pancreatic duct strictures with or without mass require EUS-FNA 6, 4
Mural nodule or enhanced solid component, main pancreatic duct ≥10 mm, symptoms, and positive FNA results or high suspicion of malignancy require surgical resection 6, 4

CDKN2A carriers face a uniquely high risk of developing second primary pancreatic cancers, and require concurrent surveillance for melanoma and other cancers tailored to their germline mutation status 1, 2

All surveillance and surgical management must occur at high-volume specialty centers with multidisciplinary teams experienced in managing hereditary pancreatic cancer 6, 3, 4
New-onset diabetes, unexplained weight loss, or abdominal symptoms should prompt immediate evaluation rather than waiting for the next scheduled surveillance 5